NCT01524341View on ClinicalTrials.gov

Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Malaria
Interventions
DRUG

KAE609

KAE609 was supplied as capsules for oral use.

Trial Locations (3)

10400

Novartis Investigative Site, Bangkok

63110

Novartis Investigative Site, Tak

Novartis Investigative Site, Tak Province

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY